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Little is known about the long-term neurological development of children diagnosed with
congenital Zika infection at birth. Here, we report the imaging and clinical outcomes up to
three years of life of a cohort of 129 children exposed to Zika virus in utero. Eighteen of them
(14%) had a laboratory confirmed congenital Zika infection at birth. Infected neonates have a
higher risk of adverse neonatal and early infantile outcomes (death, structural brain
anomalies or neurologic symptoms) than those who tested negative: 8/18 (44%) vs 4/111
(4%), aRR 10.1 [3.5–29.0]. Neurological impairment, neurosensory alterations or delays in
motor acquisition are more common in infants with a congenital Zika infection at birth: 6/15
(40%) vs 5/96 (5%), aRR 6.7 [2.2–20.0]. Finally, infected children also have an increased
risk of subspecialty referral for suspected neurodevelopmental delay by three years of life:
7/11 (64%) vs 7/51 (14%), aRR 4.4 [1.9–10.1]. Infected infants without structural brain
anomalies also appear to have an increased risk, although to a lesser extent, of neurological
abnormalities. It seems paramount to offer systematic testing for congenital ZIKV infection in
cases of in utero exposure and adapt counseling based on these results.
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In the last decade, ZIKV has spread through the Pacific Islands
1
and the Americas2, leading to a worldwide epidemic. It is now
well demonstrated that ZIKV is associated with multiple con-
genital abnormalities, particularly affecting the central nervous
system3–5. Long-term disabilities, including cerebral palsy, epi-
lepsy, and neurosensory alterations have been described in infants
from the American and Brazilian cohorts6–9. Infants included in
these cohorts were mostly affected by congenital Zika Syndrome
(CZS) with cerebral anomalies or neurological impairments at
birth. The evolution of those with a laboratory-confirmed con-
genital infection but who were asymptomatic and without cerebral
anomalies at birth remains poorly described. Overall, the corre-
lation between laboratory testing for congenital ZIKV infection at
birth and long-term disability including sensory and cognitive
deficits is still lacking and may have major clinical and public
health implications10.
The French Guiana Western Hospital Center (CHOG, Centre
Hospitalier “Franck Joly”, referral center for western French
Guiana), was confronted with the ZIKV epidemic from January to
September 2016. In a previous study of a cohort of ZIKV-infected
pregnant women followed at the CHOG, we estimated that 279
infants were liveborn to these mothers11. Here, using a subset of
these infants, we show that those with a laboratory-confirmed
congenital Zika infection at birth have higher risks of imaging and
clinical adverse outcomes at 2 months, 2 years, and 3 years of life
than those tested negative at birth.
Results
Study population. Between January and September 2016, 132
newborns from 128 ZIKV-infected mothers (four dichorionic
twins) were enrolled for prospective follow-up at the pediatric
clinic of the CHOG. Three of them were not tested for ZIKV
before postpartum discharge and were excluded. Among 129
children tested for ZIKV at birth, 18 (14.0%) had a laboratory-
confirmed congenital infection and 111 (86.0%) tested negative
(details of fetal and neonatal testing are presented in Supple-
mentary Table 1, Fig. 1 describes the enrollment).
Baseline characteristics. Median maternal age at delivery was 25
and 26 years old in the group of congenital infections and the
negative group, respectively. Maternal infection diagnosed in the
first trimester of pregnancy was more frequent in mothers of
infected newborns (38.9% vs 24.3%). Cesarean section delivery
occurred more often in these mothers (27.8% vs 12.6%). Twins
were also more frequent among infected newborns (11.1% vs
5.4%). Alcohol and drug consumption was more frequent in
mothers of newborns that tested negative for ZIKV at birth
(10.8% vs 5.6%). Other environmental or recreative exposures
and co-morbidities during pregnancy including low socio-
economic status, infant sex, rate of prematurity, and neonatal
adaptation were not different between these groups (Table 1).
Three mothers had an identified TORCH (toxoplasmosis, rubella,
cytomegalovirus, and Herpes simplex virus) co-infection during
pregnancy, however, newborns tested negative during the preg-
nancy and at birth (one primary toxoplasmosis and two primary
cytomegalovirus infections).
Neonatal and early infantile outcomes. Among 18 neonates with
a confirmed congenital ZIKV infection at birth, 8 (44.4%) were
identified to have an adverse outcome during their first 2 months
of life: 6 (33.3%) had severe structural brain anomalies, of whom
one died in his first day of life (CZS with arthrogryposis and
severe brainstem dysfunction) and two others had severe neu-
rological symptoms. The risk of adverse outcomes at 2 months
was higher for infected infants compared with those tested
negative at birth (4/111, 3.6%), even after adjustment for maternal
infection diagnosed in the first trimester of pregnancy: aRR 10.1
[95% CI 3.5–29.0]. When considering only infants without
structural brain anomalies, the risk of severe neurological
symptoms was also higher in those diagnosed with a congenital
ZIKV infection (2/12, 16.7% vs 1/108, 0.9%): aRR 20.5 [95% CI
2.0–207.7] (Table 2 and Fig. 2). At 2 months of life, microcephaly,










N= 18 N= 111
Maternal age at birth
(years)—median
(min–max)
25 (18–38) 26 (18–43) 0.09
Maternal socioeconomic status—no. (%)
Low 6 (33.3%) 38 (34.2%) −0.02
Moderate 8 (44.4%) 46 (41.4%) 0.06
High 1 (5.6%) 8 (7.2%) −0.07
Unknown 3 (16.7%) 19 (17.1%) −0.01
Maternal exposure during pregnancy—no. (%)
Alcohol consumption 1 (5.6%) 12 (10.8%) −0.19
Drug use 0 (0.0%) 1 (0.9%) 0.13
Current smoker 1 (5.6%) 5 (4.5%) 0.05
Lead poisoning 1 (5.6%) 6 (5.4%) 0.01
Any maternal co-
morbiditiesπ—no (%)
3 (16.7%) 15 (13.5%) 0.09
Diabetes (previous or
gestational)
1 (5.6%) 7 (6.3%) −0.03
Vascular pathologies 1 (5.6%) 5 (4.5%) 0.05
Severe anemia 1 (5.6%) 5 (4.5%) 0.05
Co-infections* 1 (5.6%) 2 (1.8%) 0.20
Maternal Zika infection—no (%)
Symptomatic 4 (22.2%) 22 (19.8%) 0.06
Asymptomatic 14 (77.8%) 89 (80.2%) −0.06
Trimester of maternal Zika infection diagnosis—no. (%)
T1 infection 7 (38.9%) 27 (24.3%) 0.31
T2 infection 7 (38.9%) 37 (33.3%) 0.11
T3 infection 2 (11.1%) 25 (22.5%) −0.30
Unknown 2 (11.1%) 22 (19.8%) −0.24
Dichorionic twins 2 (11.1%) 6 (5.4%) 0.20
Fetus gender—no. (%)
Female 10 (55.6%) 63 (56.8%) −0.02
Male 8 (44.4%) 48 (43.2%) 0.02
Term at birth (weeks’
gestation)—median
(min–max)
39 (32–41) 39 (36–41) −0.18
Premature birth <37 wg 1 (5.6%) 6 (5.4%) 0.01
Mode of delivery—no. (%)
Normal 13 (72.2%) 97 (87.4%) −0.38
C-section 5 (27.8%) 14 (12.6%) 0.38
Neonatal adaptation
Abnormal Apgar score
(<6 at 5 min)—no (%)
2 (11.1%) 13 (11.7%) −0.02
Abnormal lactate level
(> 4.5)—no (%)
2 (11.1%) 16 (14.4%) −0.09
Age, weight, and term variables are presented as a median with extreme values. For qualitative
variables, absolute frequencies and relative frequencies (percentages) are presented. Baseline
characteristics are compared between groups using standardized differences.
Alcohol consumption was defined as ongoing consumption during the pregnancy after its
diagnosis. Current smoking was defined as ongoing smoking during pregnancy after its
diagnosis. Baseline characteristics were considered unbalanced if standardized differences (Std
diff) were > 0.1.
πincluding multiple maternal co-morbidities.
*One primary cytomegalovirus infection in the infected group; one primary CMV and one
primary toxoplasmosis infection in the control group.
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abnormal evoked otoacoustic emission (OAE) testing, and ocular
anomalies were confirmed in 2/17 (11.8%), 2/12 (16.7%), and
3/10 (30%) infected infants; and in 1/111 (0.9%), 1/43 (2.3%), and
2/34 (5.9%) infants that tested negative at birth, respectively
(Table 3). Head circumference (HC) and weights, according to
the results of congenital Zika infection testing, are presented
in Fig. 3.
Outcomes at 2 years of life. At 2 years of life, 15 children with a
confirmed congenital ZIKV infection at birth and 96 who tested
negative at birth were still followed at the CHOG pediatric clinic.
Among infected children, 5/15 (33.3%) had neurologic
impairments: 2 with cerebral palsy, 3 with severe dystonia, and
3 with seizures. Two of those with neurologic impairments had
motor acquisition delays, partial, or complete blindness, and one
had hearing deficits. Hearing impairment was also diagnosed in
another infected child, without neurologic impairments (Table 4).
Overall, the risk of adverse outcomes at 2 years of life was higher
in infected children (6/15, 40.0%) compared with those that tested
negative at birth (5/96, 5.2%), even when only considering
children without structural brain anomalies (2/10, 20.0% vs 3/93,
3.2%): aRR 6.7 [95% CI 2.2–20.0] and aRR 6.2 [1.2–33.0],
respectively (Table 2 and Fig. 2).
Neurodevelopment at 3 years of life. Eleven (11/17, 64.7%)
children of the infected group and 51 (51/111, 45.9%) children of
the group that tested negative at birth presented for neurodeve-
lopmental screening in August and September 2019. The median
age at evaluation was 35 months in the infected group and
36 months in the group of children that tested negative at birth.
A developmental score below−2SD (“Referral” zone) in at least one
domain was observed in 7/11 (63.6%) infected children, the cog-
nitive and language domain being the most affected (6/11, 54.5%).
Details of the Child Development Assessment Scale (CDAS) are
presented in Table 4 and Fig. 4. Children with a confirmed con-
genital ZIKV infection at birth had a higher risk of a CDAS score in
the “referral zone” (<−2SD) compared with children that tested
negative (7/51, 13.7%), even when considering only those without
structural brain anomalies: aRR 4.4 [1.9–10.1] and aRR 3.0
[1.0–9.0], respectively (Table 2 and Fig. 2).
Children with a CDAS score in the “referral zone” were the same
who had an adverse outcome at 2 years among the infected. In
addition, one infected infant without structural brain anomalies and
who remained asymptomatic until 2 years of age was screened as at
risk for developmental delay at 3 years of life.
Effect-modifiers. Exposures during pregnancy, maternal age, co-
morbidities, socioeconomic status, infant sex, twins, prematurity,
and the mode of delivery were tested as effect-modifiers on main
outcomes, and no interactions were identified. The presence of
structural brain anomalies, however, was an effect-modifier for
severe neurological symptoms at 2 months of life, and on adverse
outcomes at 2 and 3 years of life. A sub-analysis of children with
and without structural brain anomalies is presented in Table 2.
Discussion
Main results. In this study, we assessed the development of
children with laboratory-confirmed congenital ZIKV infection
up to 3 years of age. Our results indicate that infected neonates
have a higher risk of neurological symptoms at birth (27.8%),
Newborns from ZIKV-infected mothers enrolled at birth (n=132)
Zika virus RNA amplification by RT-PCR on placenta, 
umbilical / neonatal blood and / or urine, Serology on 
neonatal blood (n=129)
Not tested at birth (n=3)
Neonates with a confirmed congenital Zika 
infection at birth, evaluated by prenatal & 
transfontanellar US +/- CT +/- MRI (n= 18)
Neonates tested negative for congenital Zika 
infection at birth, evaluated by prenatal & 
transfontanellar US +/- CT +/- MRI (n= 111) 
Pediatric clinical examination at 2m (n=17)
- Otoacoustic emission testing (n=12)
- Fundoscopy (n=10)
Pediatric clinical examination at 2m (n=111)
- Otoacoustic emission testing (n=43)
- Fundoscopy (n=34)
1 neonatal death with CZS (5.6%)
Pediatric clinical examination at 6, 9 and 
12m (n=15)
Pediatric clinical examination at 6, 9 and 
12m (n=97)
2 lost to follow-up (11.8%) 14 lost to follow-up (12.6%)
Pediatric clinical examination at 24m (n=15) Pediatric clinical examination at 24m (n=96)
1 lost to follow-up (1.0%)
Pediatric clinical examination at 33-39m, 
including a CDAS evaluation (n=11)
Pediatric clinical examination at 34-40m, 
including a CDAS evaluation (n=51)
4 lost to follow-up (26.7%) 45 lost to follow-up (46.9%)
Fig. 1 Flowchart of newborns exposed to Zika virus in utero. All newborns from Zika-infected mothers, living in western French Guiana and followed
at the pediatric clinic of the CHOG, were enrolled in this cohort following an informed consent process. At birth, they underwent clinical examination
(including anthropometric measurements and a special focus on the neurological status), transfontanellar ultrasound (US), and testing for congenital Zika
infection (PCR on urine, blood, and placenta; serology; and testing in cerebrospinal fluid if symptomatic). After postpartum discharge, they were recalled at
2, 6, 9, 12, 18, and 24 months of life for a pediatric examination. At 3 years of life (33–42 months), they were recalled for an evaluation of their development
using the Child Development Assessment Scale (CDAS).
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even when no structural brain anomalies are observed (16.7%),
as compared with neonates that tested negative at birth (0.9%).
At 2 years of age, infection at birth was still associated with a
higher risk of neurologic impairment and/or neurosensory
alteration (40.0% vs 5.2%). At 3 years of life, suspicion of
neurodevelopmental delay (<−2SD) was more common in
children that tested positive at birth (63.6% vs 13.7%). All those
that tested positive at birth and had structural brain anomalies
had evidence of neurodevelopmental delay (<−2SD) (4/4),
compared with less than half in those without structural brain
anomalies (3/7).
Interpretation. Structural brain malformations and ocular
anomalies associated with congenital Zika infection have been well
described worldwide, particularly in CZS5,7,12–16. Developmental
outcomes of infants exposed to ZIKV in utero have been studied
less extensively, often lacking stratification by infant ZIKV infection
status at birth. The study by Nielsen-Saines and colleagues identi-
fied similar findings to us including abnormal neurodevelopmental
and/or ophthalmological or auditory assessments in 31.5% of
children evaluated between 7 and 32months of age17. In this study,
the cognitive and language domain was also the most affected
(35% of 146 children). When comparing neuroimaging findings to
neurodevelopmental performance in ZIKV-exposed infants, Lopes
Moreira et al.6 noted a significant association between normal
results on brain imaging and higher Bayley-III scores. However,
they failed to predict severe developmental delay in 2% of children
and normal development in 16%. Similarly, in our cohort overall
(i.e., regardless of ZIKV infection status at birth), ~20% (10/56) of
the children without structural brain anomalies had evidence of
neurodevelopmental delay in at least one domain at 3 years of life,
whereas one-third (2/6) with brain anomalies did not. The results of
the Colombian cohort reported by Mulkey et al.18 indicate that
neurodevelopmental delay in a child that is healthy at birth could
worsen with age.
Brasil et al.19 performed a study stratifying infants by their
ZIKV infection status at birth. They described neurodevelop-
mental outcomes of 130 children born to ZIKV-infected
mothers, of whom 84 (65%) tested positive for ZIKV between
birth and 1 year of age. They could only observe trends towards
an association between laboratory-confirmed infection and
specific abnormalities (structural brain anomalies, vision and
hearing deficits, abnormal neurological exam, developmental
delay). The disparity between their results and ours may be
explained by the difference in testing strategy for congenital
infections, as a positive result after postpartum discharge is not
able to differentiate congenital infections from post-natal
acquired infections. As a result, a potentially higher proportion
of exposure misclassification may have biased their estimates
towards a null association.
The impact of the trimester of maternal infection is contra-
dictory in some studies. In the cohort from Rio de Janeiro, the
authors found that adverse outcomes were not correlated with the
trimester of maternal infection3. Other cohorts have identified
higher rates of brain structural anomalies and CZS in cases of
maternal infection in the first trimester4,16,20. In our study, we
observed a higher proportion of infants with neonatal, early
infantile, or adverse outcomes at 2 and 3 years of life after
maternal infection diagnosed in the first trimester of pregnancy,
although this difference was not significant as our study does not
appear to be sufficiently powered to conclude on this covariate
(Supplementary Table 3). Moreover, our study reports the
trimester at infection diagnosis but does not permit to accurately
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Overall, the results from our study along with those from
previously published studies seem to indicate that a laboratory-
confirmed congenital ZIKV infection at birth could be associated
with higher risks of long-term outcomes, even in children without
structural brain anomalies. As a normal antenatal and neonatal
evaluation cannot provide complete reassurance for children
exposed to ZIKV in utero, it seems paramount to offer systematic
testing for congenital ZIKV infection at birth in cases of in utero
exposure and to adapt counseling according to these results.
Study limitations. The first limitation of this study is the pro-
portion of individuals lost to follow-up reducing the sample size
from 129 to 111 after 2 years and to 62 after 3 years and intro-
ducing a potential selection bias. Loss to follow-up is critical in
determining a study’s validity as patients lost to follow-up might
have a different outcome than those who complete the study. In
our study, although not significant, the proportion of loss to
follow-up was higher among children who tested negative at birth
compared with those with a confirmed congenital infection (60/
111, 54.1% vs 6/17, 35.3%, p= 0.1494, Std diff= 0.38), which
suggests a potential selection bias on the outcome. Yet, it is dif-
ficult to know if the loss to follow-up has selected the more severe
cases or not. One would argue that the lack of clinical concern by
parents, particularly in asymptomatic cases, might have driven
the loss to follow-up. This would have overestimated the absolute
risks of infantile adverse outcomes and the suspicion of neuro-
development delay in the cohort, particularly in those that tested
negative at birth. Thus, absolute risk in this study should be
considered carefully.
Another source of potential selection bias is linked to practical
limitations for follow-up at the CHOG for newborns from
mothers living along the Maroni River or in isolated areas in
Suriname. Among the newborns born at the CHOG, only those
that would be followed at the CHOG pediatric clinic were
enrolled, resulting in the exclusion of 35% of the CHOG-born
newborns from ZIKV-infected mothers, leading to the initial
inclusion of only 129 infants. This might have selected infants
stemming from families with a higher socioeconomic status. This
would have led to a possible underestimation of the absolute risk
although unlikely as this selection impacted both groups.
The second limitation of this study is the testing performance
to confirm congenital infections. In fetuses and neonates, it has
been demonstrated that viremia is transient in blood, amniotic
fluid, and urine21. Thus, the window to detect congenital
infections using reverse transcription-polymerase chain reaction
(RT-PCR) may be shorter than for other congenital infections
(i.e., CMV). In infants, congenital ZIKV infections are difficult to
confirm retrospectively, owing to serological test cross-reaction
and the possibility of infection after birth in the context of
continuous exposure. To avoid false-negative or false-positive
results, neonatal serology was performed before postpartum
discharge. As no other flaviviridae was circulating significantly
during this period, we considered the risk of cross-reactions low,
and a positive neonatal IgM without positive RT-PCR was
considered as a laboratory-confirmed congenital infection,
although these would be considered as probable cases per CDC
definitions22. We tried to reduce the risk of misclassification
biases by performing neonatal testing on different samples
(Appendix 1), however, we cannot exclude that some newborns
Adverse outcomes at 2m
• Structural brain anomalies
• Severe neurologic symptoms
Adverse outcomes at 2y
• Neurologic impairments
• Delay in motor acquisitions
• Neurosensory alterations
Adverse outcomes at 3y
• Motor domain <-2SD














Fig. 2 Main outcomes at 2 months, 2 years, and 3 years of life. Relative risks of adverse outcomes at 2 months (m), 2 years (y), and 3 years of life,
associated with laboratory-confirmed congenital Zika infection at birth are estimated using generalized linear models, adjusted on maternal infection
diagnosed in the first trimester, and presented with 95% confidence intervals (95% CI). SD standard deviations.
Table 3 Neonatal and early infantile outcomes, from birth to
2 months of life.
Neonatal and early infantile








N= 18 N= 111
Status at 2 months of life—no (%)
Alive 17 (94.4%) 111 (100.0%) 0.1400
Neonatal demise 1 (5.6%) 0 (0.0%) 0.1400
Microcephaly <−3SD
At birth*—no (%) 2 (11.1%) 1 (0.9%) 0.0077
At 2 months**—no (%)a 2/17 (11.8%) 1 (0.9%) 0.0077
Weight <−2SD
At birth—no (%)* 2 (11.1%) 12 (10.8%) 0.9256
At 2 months**—no (%)a 2/17 (11.8%) 8/111 (7.2%) 0.5656
Structural brain anomalies—no (%) 6 (33.3%) 3 (2.7%) <0.0001
Cortical development anomaly 4 (22.2%) 0 (0.0%) <0.0001
Corpus callosum anomaly 4 (22.2%) 2 (1.8%) 0.0030
Calcifications or cystic lesions 5 (27.8%) 1 (0.9%) <0.0001
Posterior fossa anomaly 4 (22.2%) 0 (0.0%) <0.0001
Ventriculomegaly 4 (22.2%) 1 (0.9%) 0.0010
Ocular anomalies—no (%)
Microphtalmy 1 (5.6%) 0 (0.0%) 0.1400
Fundoscopy anomalies 3/10 (30.0%) 2/34 (5.9%) 0.0330
Subretinal hemorrhage 2/10 (20.0%) 1/34 (2.9%) 0.0599
Chorioretinal lacunae 2/10 (20.0%) 1/34 (2.9%) 0.0599
Macula atrophy 1/10 (10.0%) 1/34 (2.9%) 0.3462
Abnormal otoacoustic emission—no (%) 2/12 (16.7%) 1/43 (2.3%) 0.1170
Severe neurologic symptoms—no (%) 5 (27.8) 1 (0.9%) <0.0001
Arthrogryposis 1 (5.6%) 0 (0.0%) 0.1400
Hypertonia 3 (16.7%) 0 (0.0%) 0.0020
Dysphagia/swallowing disorders 2 (11.8%) 0 (0.0%) 0.0190
Seizures 1 (5.6%) 1 (0.9%) 0.2610
NICU admission—no (%) 3 (16.7%) 14 (12.6%) 0.6372
Weight and head circumference (HC) variables are presented as medians with extreme values.
For qualitative variables, absolute frequencies and relative frequencies (percentages) are
presented. Secondary outcomes were compared across the groups using χ2, Fischer, and
Wilcoxon tests.
a128 alive infants evaluated at 1 and 2 months of life.
*According to Intergrowth21 charts.
**According to WHO Child Growth Standards. Exact p values were estimated by χ2, Fischer, or
Wilcoxon tests (two-sided).
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Age (Months) Age (Months)
Fig. 3 Head circumference and weight in children tested positive and negative for congenital Zika infection at birth. Head circumferences (in
centimeters) and weights (in kilograms) are presented for each time point of this study (birth, 1 month, 2 months, 1 year, 2 years, 3 years). Boxes represent
median and interquartile range (IQR), whiskers represent range excluding outliers >1.5× IQR from upper or lower quartile, and circles represent outliers. Z-
(blue): Children tested negative at birth for congenital Zika infection; Z+ (red): children tested positive at birth for congenital Zika infection. n= 129
neonates at birth (18 Z+/ 111 Z−), n= 128 infants at 1 and 2 months (17 Z+/ 111 Z−), n= 112 infants at 12 months (15 Z+/ 97 Z−), n= 111 children at
24 months (15 Z+/ 96 Z−), n= 62 children at 36 months (11 Z+/51 Z−).
Table 4 Outcomes up to 3 years of life.
Children outcomes—up to 3 years of life Confirmed congenital infection at birth Negative testing at birth p
N= 15 N= 97
Microcephaly <−3SD*
At 1 year 2 (13.3%) 1 (1.0%) 0.0060
At 2 yearsa 2 (13.3%) 1/96 (1.0%) 0.0080
At 3 yearsb 2/11 (9.1%) 1/51 (2.0%) 0.0237
Weight < 5th percentile*
At 1 years 2 (13.3%) 6 (6.2%) 0.2908
At 2 yearsa 2 (13.3%) 6/96 (6.3%) 0.2947
At 3 yearsb 1/11 (9.1%) 3/51 (5.9%) 0.6944
Neurologic impairments at 2ya—no (%) 5 (33.3%) 4/96 (4.2%) 0.0001
Cerebral palsy 2 (13.3%) 0/96 (0.0%) 0.0170
Severe dystonia or tremors 3 (20.0%) 3/96 (3.1%) 0.0070
Seizures 3 (20.0%) 2/96 (2.1%) 0.0170
Motor acquisitions
Age at sitting position (m)—median (min–max) 6 (3–24) 6 (4–11) 0.8113
Delay for sitting position (>9m)–no (%) 2 (13.3%) 1 (1.0%) 0.0060
Age at walking (m)—median (min–max) 11 (8–24) 11 (7–17) 0.3289
Delay for walkinga (>18m)—no (%) 1 (6.7%) 0/96 (0.0%) 0.0110
Vision and hearing evaluation
Impaired response to visual stimuli—no (%) 2 (13.3%) 1 (1.0%) 0.0060
Impaired response to auditory stimuli—no (%) 2 (13.3%) 1 (1.0%) 0.0060
Age at CDAS evaluationb (m)—median (min–max) 35 (33–39) 36 (34–40) 0.7665
Global assessment – no (%)
“Comfort” zone (>−1SD) 3/11 (27.3%) 30/51 (58.8%) 0.0572
“To be monitored” zone ([−2SD; −1SD]) 1/11 (9.1%) 14/51 (27.5%) 0.1972
“Referral” zone (<−2SD) 7/11 (63.4%) 7/51 (13.7%) 0.0003
Motor domain—no (%)
“Comfort” zone (>−1SD) 7/11 (63.4%) 47/51 (92.2%) 0.0105
“To be monitored” zone ([−2SD; −1SD]) 2/11 (18.2%) 3/51 (5.8%) 0.1742
“Referral” zone (<−2SD) 2/11 (18.2%) 1/51 (2.0%) 0.0790
Socio-emotional domain—no (%)
“Comfort” zone (>−1SD) 7/11 (63.4%) 41/51 (80.4%) 0.2280
“To be monitored” zone ([−2SD; −1SD]) 0/11 (0.0%) 4/51 (7.8%) 0.3369
“Referral” zone (<−2SD) 4/11 (36.4%) 6/51 (11.8%) 0.0442
Cognitive and language domain—no (%)
“Comfort” zone (>−1SD) 3/11 (27.3%) 32/51 (62.7%) 0.3140
“To be monitored” zone ([−2SD; −1SD]) 2/11 (18.2%) 16/51 (31.4%) 0.3820
“Referral” zone (<−2SD) 6/11 (54.5%) 3/51 (5.9%) <0.0001
For qualitative variables, absolute frequencies and relative frequencies (percentages) are presented. Secondary outcomes were compared across the groups using χ2, Fischer, and Wilcoxon tests.
a111 infants evaluated at 2 years of life, including 15 with laboratory-confirmed congenital ZIKV infection.
b62 children evaluated at 3 years of life using the CDAS, including 11 with laboratory-confirmed congenital ZIKV infection.
*According to WHO Child Growth Standards <2 years and CDC growth charts >2 years of life. Exact p values were estimated by χ2, Fischer, or Wilcoxon tests (two-sided).
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classified as uninfected had undetectable viremia and immune
response at birth. To increase the sensitivity of neonatal testing,
we included positive RT-PCR on placental samples in the
definition of laboratory-confirmed congenital ZIKV infections23.
However, we did not observe contradictory results in cases of
infected placentas, as all also had a positive IgM and/or RT-PCR
in fetal/neonatal samples.
The follow-up of infants and children was based on the French
recommendations24 and adapted to local capacities, but we
cannot exclude that routine MRI, auditory brainstem response
testing, and consultation with a pediatric neurologist, as
recommended by the CDC, would have diagnosed more subtle
and specific signs of congenital ZIKV infection.
The third limitation is the presence of a language barrier. Some
children or mothers have difficulties when using the French
language. These difficulties could have wrongly led to a lower
score when using the French version of the CDAS to evaluate the
cognitive & language domain, resulting in misclassification of the
outcome. The two practitioners who evaluated these children,
however, were also able to speak the local language and translate
questions, limiting the poor understanding of the CDAS
assessment. This would have led to an overestimation of the
difficulties in the cognitive and language domain, however, this
issue would likely have impacted both groups equally.
The last limitation was that a control group of children born
from uninfected mothers who underwent neurodevelopmental
testing using the CDAS was not available. In the general
population, a normal distribution of neurodevelopmental scores
would be expected when using a standardized tool such as the
CDAS, but this test has never been used in French Guiana and
cognitive scales, in particular, may include items that could be
influenced by the cultural context. In a cross-sectional study
evaluating the neurodevelopment of Polynesian infants born
during the ZIKV outbreak versus a control group of Canadian
infants, Subissi et al.25 described that confounding factors such as
socioeconomic status and cultural factors may play an important
role in infantile neurodevelopmental assessment.
Methods
Study settings and participants. This prospective cohort study included new-
borns from mothers infected with ZIKV during pregnancy that were followed at
the CHOG after the 2016 ZIKV epidemic. The CHOG offers the only maternity
and neonatal intensive care units in western French Guiana. During the ZIKV
epidemic (January to September 2016), all pregnant women in the territory
underwent laboratory screening by ZIKV serology in each trimester and at delivery,
as well as RT-PCR in urine and plasma samples for those with symptoms.
All infected women were followed in the fetal medicine unit of the CHOG. Fetal
ultrasound (US) examinations were performed every 3–4 weeks using E8 and E10
Voluson scanners with abdominal (RM6C) and transvaginal (RIC5-9-D)
transducers (General Electric Healthcare, Zipf, Austria). Additional investigations
(MRI, computed tomography (CT), amniocentesis) were performed based on US
results and after a discussion with a multi-disciplinary team. All neonates from
ZIKV-infected mothers living in the area (Fig. 5) were offered ongoing follow-up at
the CHOG until the third year of life and participation in this study. Asymptomatic
neonates from mothers living along the Maroni River, outside of the Saint-Laurent
du Maroni area, were discharged with their mother after day 3–5 postpartum and
were followed in the nearest primary healthcare center, and only returned to the
CHOG in cases of emergency or need for advanced care. Thus, these infants were
not included in this cohort.
The study received ethics approval from the institutional review board of the
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Fig. 4 Childhood development at 3 years of life. All children followed for in utero ZIKV exposure were recalled for a developmental evaluation using the
Child Development Assessment Scale at 3 years of life (33–42 months, n= 62). Normal results are classified in the “comfort” or “blue” zone (>−1 standard
deviation [SD]). Intermediate results are classified in the “to be monitored” or “gray” zone (−2SD; −1SD). Suspicion of delays is classified in the “referral”
or “red” zone (<−2SD). The motor, socio-emotional, and cognitive & language domains were evaluated using this scale. Results of these domains were
synthesized in a global evaluation.
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Laboratory testing for congenital ZIKV infection and exposure definition.
During pregnancy, RT-PCR on amniotic fluid was offered for cases with fetal
anomalies or if an amniocentesis was performed for another indication (i.e.,
aneuploidy diagnosis). After birth, all newborns underwent ZIKV serology for
detection of specific IgM before day 3 of life. RT-PCRs were performed in cord
blood, neonatal urine, and placenta. Additional testing on cerebrospinal fluid was
proposed in cases with neurological symptoms or demise.
We defined a laboratory-confirmed congenital ZIKV infection either by positive
RT-PCR from at least one fetal/neonatal sample (amniotic fluid, cerebrospinal
fluid, urine, blood, placenta) or identification of specific IgM in neonatal blood or
in cerebrospinal fluid.
Neonates from ZIKV-infected mothers without a confirmed congenital ZIKV
infection were classified as controls.
Molecular and serologic testing was performed at the French Guiana National
Reference Center for arboviruses (Institut Pasteur of French Guiana, Cayenne,
French Guiana) using the Realstar Zika Kit (Altona Diagnostics GmbH, https://
altona-diagnostics.com) for RT-PCR, and in-house enzyme-linked immunosorbent
assay (ELISA) and IgM antibody-capture (MAC) ELISA for serologic testing. The
limit of detection for serum samples tested using the Realstar Zika Kit was 0.61
(95% CI 0.39–1.27) copies/μL, and a cycle threshold value <37 was considered
positive. The following primers were used: (1) ZIKV 1086 1086–1102 CCGCTG
CCCAACACAAG; (2) ZIKV 1162c 1162–1139 CCACTAACGTTCTTTTGCAG
ACAT; (3) ZIKV 1107-FAM 1107–1137 AGCCTACCTTGACAAGCAGTCAGA
CACTCAA. ELISA and MAC-ELISA testing was based on whole virus antigens,
with a positive result defined as three standard deviations above the negative
control value. Its sensitivity for specific IgM detection was estimated at 98% after
day 7 from symptoms onset in an adult cohort26.
Details of maternal, fetal, and neonatal testing are available in our previous
studies4,11. Placentas were sampled and tested according to the method described
in our dedicated study, which also corresponds to what was proposed by Seferovic
and colleagues23,27.
Outcome definition and time of measurement. Newborns underwent cerebral
imaging and neurosensory testing and were followed by a pediatrician up to 3 years of
life. The last evaluation included a neurodevelopmental screening using the CDAS28.
Neonatal and early infantile outcomes. All ZIKV-exposed neonates, regardless of
their testing result at birth, underwent clinical examination with special attention
to anthropometric measurements, neurological status, and signs of infection. The
HC measurements were confirmed 24 h after birth to avoid the effects of delivery
sequelae. In addition to clinical examination, they were assessed by transfontanellar
US, hearing evaluation by OAE testing, and fundoscopy (1–2 months after birth).
Every abnormal examination was reconfirmed, and more investigations (MRI, CT)
were requested depending on the clinical picture.
Neonatal and early infantile adverse outcomes were defined as neonatal death
(between birth and 2 months of life, intrapartum demise not included), structural
brain anomalies, or severe neurological symptoms (according to Pomar et al., BMJ,
2018; Prenat diagnosis, 2019)11,29.
Follow-up and outcomes at 2 years of life. All infants enrolled were scheduled
for medical consultation at the CHOG pediatric clinic at 2, 6, 9, 12, 18, and
24 months of life. These pediatric examinations included parental questioning on
infant development, anthropometric measurements, assessment of motor acquisi-
tion, a neurological examination, and an auditory and visual assessment, following
the French high Council of Public Health (HCSP) recommendations24.
Adverse outcomes at 2 years of life were defined as the observation of
neurologic impairment (cerebral palsy, severe dystonia, tremors, or seizures),
motor acquisition delay (sitting position >9 months or walking >18 months of age),
or neurosensory alterations (impaired response to visual or auditory stimuli) until
the age of 24 months.
Neurodevelopmental outcomes. In August and September 2019, at 3 years of life,
the children were screened for neurocognitive development using the French version
of the CDAS28. Adapted to children 0–5 years of age, the results allow the user to
evaluate the child’s cognitive, language, motor, and social-emotional development
using a validated and standardized scale. Results in the “comfort zone” (blue, >−1SD)
indicate normal development. Results in the “to be monitored zone” (gray, [−2SD to
−1SD]) suggest that interventions with the child should be adapted according to
identified difficulties and that the child should be reassessed later. Finally, results in
the “referral zone” (red, <−2SD) indicate that the child should be referred for an
exhaustive developmental assessment. To avoid any bias of administration, all chil-
dren were evaluated by two medical doctors trained to perform the CDAS test and
blinded for the results of congenital Zika infection testing.
A suspected delay in neurodevelopment was defined as a CDAS below −2SD
(“referral zone”) in at least one domain at 3 years of life.
Mitigation of bias. In the context of French Guiana, infants have an increased risk
of loss to follow-up after postpartum discharge, as some live in isolated areas and
are followed in primary care centers. These infants were not included in the cohort
to avoid misclassification bias. In infants enrolled in the cohort, when missed
appointments occurred, the parents were recalled to schedule another evaluation.
We did not enroll infants referred to the CHOG for advanced care who were not
included initially in the cohort, to avoid selection biases.
OAE testing was implemented in May 2016 and infants born before that time
were not systematically tested at birth. After the epidemic peak, we encountered
human and technical limitations to perform fundoscopy in all children born from
ZIKV-positive mothers. To avoid selection and classification biases, we did not
consider abnormal fundoscopies or OAE in primary outcomes. Instead, we
considered an abnormal response to auditory or visual stimuli in infancy, as all the
infants were tested for these outcomes.
Statistical analysis. Baseline characteristics of mothers and newborns were
obtained at enrollment and presented as absolute and relative frequencies for those
diagnosed with a laboratory-confirmed congenital Zika infection at birth and those
that tested negative. Timing of maternal infection diagnosis was estimated based on
symptom onset or on laboratory results in cases of asymptomatic infection; and
grouped into first or second and third trimesters for the analysis. Gestational age at
birth was considered as a binary variable for the analysis (“prematurity < 37 wg”).
Standardized differences were calculated to compare baseline characteristics of
patients with laboratory-confirmed congenital ZIKV infection at birth to those who
tested negative. These characteristics were considered unbalanced when the
standardized difference was >0.1.
The relative risks (RR) associated with laboratory-confirmed congenital ZIKV
infection were assessed using generalized linear models, and were adjusted (aRR)
for confounding factors (trimester at maternal ZIKV infection diagnosis), and
controlled for potential interactions with exposures during pregnancy, maternal
age, co-morbidities, and socioeconomic status, infant gender, twins, prematurity
and the mode of delivery. Structural brain anomalies were also tested as effect-
modifiers for severe neurological symptoms, adverse outcomes at 2 years of life,
and suspicion of neurodevelopmental delay <−2SD. In the case of interaction, the
analysis was stratified for effect-modifiers.
We performed a complete case analysis, thus using different denominators for
outcomes at 2 months, 2 years, and 3 years of life.
Data were collected using Excel software and analyzed using Stata 15 (Stata
Corporation, College Station, TX, USA).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data that underlie the results are provided with this paper (supplementary
information). Other individual participant data will be shared with researchers who
Western French Guiana
Saint-Laurent du Maroni area
CHOG (Referral center with maternity and NICU)
Primary care centers
Fig. 5 Healthcare services in western French Guiana. All newborns from
Zika-infected mothers, living in western French Guiana (within the red
lines) and followed at the pediatric clinic of the CHOG (large red dot), were
enrolled in this cohort. Asymptomatic neonates from mothers living outside
of the Saint-Laurent du Maroni area (blue area), were discharged after day
3–5 postpartum and were followed in the nearest primary healthcare center
(small red dot).
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provide a methodologically sound proposal for the multicentric study, particularly
individual participant data meta-analysis. Proposals should be directed to leo.
pomar@chuv.ch. Source data are provided with this paper.
Code availability
The codes used in Stata 15 software to clean, analyze and present Tables 1–4 are provided
with this paper (“Supplementary Codes”).
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